Signal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalks

Journal of Clinical Medicine

Volumn 5, Issue 4, 2016, Pages

  Zhang, Jingyu ^a   Tian, Xiao Jun ^a   Xing, Jianhua ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

EMT; Modeling; SHH; Signaling transduction pathways; TGF ; WNT

Indexed keywords

BETA CATENIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLOPAMINE; E1A ASSOCIATED P300 PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN P15; PROTEIN P53; RHO FACTOR; SMAD PROTEIN; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; VITAMIN D; WNT PROTEIN;

BIOINFORMATICS; BREAST CANCER; CANCER GROWTH; DRUG DESIGN; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HYPOXIA; METABOLOMICS; MODEL; MOLECULAR BIOLOGY; ONCOGENE; OVARY CANCER; PANCREAS CANCER; PHARMACOPHORE; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SIGNAL TRANSDUCTION;

EID: 85114273645     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5040041     Document Type: Review

References (153)

1. Debnath, J.; Brugge, J.S. Modelling glandular epithelial cancers in three-dimensional cultures. Nat. Rev. Cancer 2005, 5, 675–688.
2. Mather, J.P.; Roberts, P.E. Introduction to Cell and Tissue Culture: Theory and Technique; Springer Science & Business Media: New York, NY, USA, 1998; Volume 1.
3. Mackenzie, T.C.; Flake, A.W. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. Blood Cells Mol. Dis. 2001, 27, 601–604.
4. Kidd, S.; Spaeth, E.; Dembinski, J.L.; Dietrich, M.; Watson, K.; Klopp, A.; Battula, V.L.; Weil, M.; Andreeff, M.; Marini, F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27, 2614–2623.
5. Hoogduijn, M.J.; Dor, F.J. Mesenchymal stem cells in transplantation and tissue regeneration. Front. Immunol. 2011, 2, 84.
6. Hematti, P.; Keating, A. Mesenchymal Stromal Cells: Biology and Clinical Applications; Springer Science & Business Media: New York, NY, USA, 2013.
7. Hay, E.D. Organization and fine structure of epithelium and mesenchyme in the developing chick embryo. Epithel. Mesenchymal Interact. 1968, 2, 31–35.
8. Thiery, J.P.; Acloque, H.; Huang, R.Y.J.; Nieto, M.A. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871–890.
9. Ten Berge, D.; Koole, W.; Fuerer, C.; Fish, M.; Eroglu, E.; Nusse, R. Wnt signaling mediates self-organization and axis formation in embryoid bodies. Cell Stem Cell 2008, 3, 508–518.
10. Lindsley, R.C.; Gill, J.G.; Kyba, M.; Murphy, T.L.; Murphy, K.M. Canonical wnt signaling is required for development of embryonic stem cell-derived mesoderm. Development 2006, 133, 3787–3796.
11. Bottcher, R.T.; Niehrs, C. Fibroblast growth factor signaling during early vertebrate development. Endocr. Rev. 2005, 26, 63–77.
12. Eastham, A.M.; Spencer, H.; Soncin, F.; Ritson, S.; Merry, C.L.; Stern, P.L.; Ward, C.M. Epithelial-mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res. 2007, 67, 11254–11262.
13. Kasai, H.; Allen, J.T.; Mason, R.M.; Kamimura, T.; Zhang, Z. TGF-β1 induces human alveolar epithelial to mesenchymal cell transition (EMT). Respir. Res. 2005, 6, 56.
14. Boyer, A.S.; Ayerinskas, I.I.; Vincent, E.B.; McKinney, L.A.; Weeks, D.L.; Runyan, R.B. TGF β 2 and TGF β 3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev. Biol. 1999, 208, 530–545.
15. Arnoux, V.; Nassour, M.; L’Helgoualc’h, A.; Hipskind, R.A.; Savagner, P. Erk5 controls slug expression and keratinocyte activation during wound healing. Mol. Biol. Cell 2008, 19, 4738–4749.
16. Carretero, M.; Escámez, M.J.; García, M.; Duarte, B.; Holguín, A.; Retamosa, L.; Jorcano, J.L.; del Río, M.; Larcher, F. In vitro and in vivo wound healing-promoting activities of human cathelicidin ll-37. J. Investig. Dermatol. 2008, 128, 223–236.
17. Yan, C.; Grimm, W.A.; Garner, W.L.; Qin, L.; Travis, T.; Tan, N.; Han, Y.-P. Epithelial to mesenchymal transition in human skin wound healing is induced by tumor necrosis factor- β through bone morphogenic protein-2. Am. J. Pathol. 2010, 176, 2247–2258.
18. Schäfer, M.; Werner, S. Cancer as an overhealing wound: An old hypothesis revisited. Nat. Rev. Mol. Cell Biol. 2008, 9, 628–638.
19. Micalizzi, D.S.; Farabaugh, S.M.; Ford, H.L. Epithelial-mesenchymal transition in cancer: Parallels between normal development and tumor progression. J. Mammary Gland Biol. Neoplasia 2010, 15, 117–134.
20. Weinberg, R. The Biology of Cancer; Garland Science: New York, NY, USA, 2013.
21. Gupta, G.P.; Massagué, J. Cancer metastasis: Building a framework. Cell 2006, 127, 679–695.
22. Fischer, K.R.; Durrans, A.; Lee, S.; Sheng, J.; Li, F.; Wong, S.T.C.; Choi, H.; El Rayes, T.; Ryu, S.; Troeger, J.; et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015, 527, 472–476.
23. Zheng, X.; Carstens, J.L.; Kim, J.; Scheible, M.; Kaye, J.; Sugimoto, H.; Wu, C.-C.; LeBleu, V.S.; Kalluri, R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015, 527, 525–530.
24. Yu, M.; Bardia, A.; Wittner, B.S.; Stott, S.L.; Smas, M.E.; Ting, D.T.; Isakoff, S.J.; Ciciliano, J.C.; Wells, M.N.; Shah, A.M.; et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science 2013, 339, 580–584.
25. Cajal, S.R.Y. Manual de Anatomia Patologica General; Casa Provincial Caridad: Barcelona, Spain, 1890.
26. Nieto, M.A. The ins and outs of the epithelial to mesenchymal transition in health and disease. Annu. Rev. Cell Dev. Biol. 2011, 27, 347–376.
27. Lamouille, S.; Xu, J.; Derynck, R. Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 2014, 15, 178–196.
28. Yingling, J.M.; Blanchard, K.L.; Sawyer, J.S. Development of TGF- β signalling inhibitors for cancer therapy. Nat. Rev. Drug Discov. 2004, 3, 1011–1022.
29. Holland, J.D.; Klaus, A.; Garratt, A.N.; Birchmeier, W. Wnt signaling in stem and cancer stem cells. Curr. Opin. Cell Biol. 2013, 25, 254–264.
30. Sullivan, N.; Sasser, A.; Axel, A.E.; Vesuna, F.; Raman, V.; Ramirez, N.; Oberyszyn, T.; Hall, B. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells. Oncogene 2009, 28, 2940–2947.
31. Allen, M.; Louise Jones, J. Jekyll and hyde: The role of the microenvironment on the progression of cancer. J. Pathol. 2011, 223, 163–177.
32. Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436, 123–127.
33. Giannoni, E.; Parri, M.; Chiarugi, P. Emt and oxidative stress: A bidirectional interplay affecting tumor malignancy. Antioxid. Redox Signal. 2012, 16, 1248–1263.
34. Montserrat, N.; Mozos, A.; Llobet, D.; Dolcet, X.; Pons, C.; de Herreros, A.G.; Matias-Guiu, X.; Prat, J. Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Hum. Pathol. 2012, 43, 632–643.
35. Lee, S.-H.; Lee, S.-J.; Jung, Y.S.; Xu, Y.; Kang, H.S.; Ha, N.-C.; Park, B.-J. Blocking of p53-SNAIL binding, promoted by oncogenic K-Ras, recovers p53 expression and function. Neoplasia 2009, 11, 22–31.
36. Wu, M.Y.; Hill, C.S. TGF- β superfamily signaling in embryonic development and homeostasis. Dev. Cell 2009, 16, 329–343.
37. Zi, Z.; Chapnick, D.A.; Liu, X. Dynamics of TGF- β /SMAD signaling. FEBS Lett. 2012, 586, 1921–1928.
38. Massagué, J. How cells read TGF- β signals. Nat. Rev. Mol. Cell Biol. 2000, 1, 169–178.
39. Heldin, C.-H.; Miyazono, K.; Ten Dijke, P. TGF- β signalling from cell membrane to nucleus through SMAD proteins. Nature 1997, 390, 465–471.
40. Wu, J.-W.; Fairman, R.; Penry, J.; Shi, Y. Formation of a stable heterodimer between SMAD2 and SMAD4. J. Biol. Chem. 2001, 276, 20688–20694.
41. Chacko, B.M.; Qin, B.; Correia, J.J.; Lam, S.S.; de Caestecker, M.P.; Lin, K. The L3 loop and C-terminal phosphorylation jointly define SMAD protein trimerization. Nat. Struct. Mol. Biol. 2001, 8, 248–253.
42. Chacko, B.M.; Qin, B.Y.; Tiwari, A.; Shi, G.; Lam, S.; Hayward, L.J.; De Caestecker, M.; Lin, K. Structural basis of heteromeric SMAD protein assembly in TGF- β signaling. Mol. Cell 2004, 15, 813–823.
43. Massagué, J.; Seoane, J.; Wotton, D. Smad transcription factors. Genes Dev. 2005, 19, 2783–2810.
44. Thuault, S.; Tan, E.-J.; Peinado, H.; Cano, A.; Heldin, C.-H.; Moustakas, A. HMGA2 and Smads co-regulate SNAIL1 expression during induction of epithelial-to-mesenchymal transition. J. Biol. Chem. 2008, 283, 33437–33446.
45. Vincent, T.; Neve, E.P.A.; Johnson, J.R.; Kukalev, A.; Rojo, F.; Albanell, J.; Pietras, K.; Virtanen, I.; Philipson, L.; Leopold, P.L.; et al. A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF- β mediated epithelial-mesenchymal transition. Nat. Cell Biol. 2009, 11, 943–950.
46. Brandl, M.; Seidler, B.; Haller, F.; Adamski, J.; Schmid, R.M.; Saur, D.; Schneider, G. IKK β controls canonical TGF β –SMAD signaling to regulate genes expressing SNAIL and SLUG during EMT in Panc1 cells. J. Cell Sci. 2010, 123, 4231–4239.
47. Choi, J.; Park, S.Y.; Joo, C.-K. Transforming growth factor- β 1 represses E-cadherin production via slug expression in lens epithelial cells. Investig. Ophthalmol. Vis. Sci. 2007, 48, 2708–2718.
48. Nakao, A.; Afrakhte, M.; Morn, A.; Nakayama, T.; Christian, J.L.; Heuchel, R.; Itoh, S.; Kawabata, M.; Heldin, N.-E.; Heldin, C.-H. Identification of SMAD7, a TGF β -inducible antagonist of TGF- β signalling. Nature 1997, 389, 631–635.
49. Xu, J.; Lamouille, S.; Derynck, R. TGF- β -induced epithelial to mesenchymal transition. Cell Res. 2009, 19, 156–172.
50. Derynck, R.; Zhang, Y.E. Smad-dependent and SMAD-independent pathways in TGF- β family signalling. Nature 2003, 425, 577–584.
51. Singh, P.; Srinivasan, R.; Wig, J.D.; Radotra, B.D. A study of Smad4, Smad6 and Smad7 in surgically resected samples of pancreatic ductal adenocarcinoma and their correlation with clinicopathological parameters and patient survival. BMC Res. Notes 2011, 4, 560.
52. Wang, H.; Song, K.; Krebs, T.L.; Yang, J.; Danielpour, D. Smad7 is inactivated through a direct physical interaction with the lim protein Hic-5/ARA55. Oncogene 2008, 27, 6791–6805.
53. Derynck, R.; Akhurst, R.J.; Balmain, A. TGF- β signaling in tumor suppression and cancer progression. Nat. Genet. 2001, 29, 117–129.
54. Kamaraju, A.K.; Roberts, A.B. Role of Rho/ROCK and p38 MAP kinase pathways in transforming growth factor- β -mediated SMAD-dependent growth inhibition of human breast carcinoma cells in vivo. J. Biol. Chem. 2005, 280, 1024–1036.
55. Kanamaru, C.; Yasuda, H.; Fujita, T. Involvement of SMAD proteins in TGF- β and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol. Res. 2002, 23, 211–219.
56. Liu, X.; Sun, Y.; Constantinescu, S.N.; Karam, E.; Weinberg, R.A.; Lodish, H.F. Transforming growth factor β -induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc. Natl. Acad. Sci. USA 1997, 94, 10669–10674.
57. Fleming, N.I.; Jorissen, R.N.; Mouradov, D.; Christie, M.; Sakthianandeswaren, A.; Palmieri, M.; Day, F.; Li, S.; Tsui, C.; Lipton, L. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013, 73, 725–735.
58. Ungefroren, H.; Groth, S.; Sebens, S.; Lehnert, H.; Gieseler, F.; Fändrich, F. Differential roles of Smad2 and Smad3 in the regulation of TGF- β 1-mediated growth inhibition and cell migration in pancreatic ductal adenocarcinoma cells: Control by Rac1. Mol. Cancer 2011, 10, 67.
59. Yakicier, M.; Irmak, M.; Romano, A.; Kew, M.; Ozturk, M. Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 1999, 18, 4879–4883.
60. Riggins, G.J.; Kinzler, K.W.; Vogelstein, B.; Thiagalingam, S. Frequency of Smad gene mutations in human cancers. Cancer Res. 1997, 57, 2578–2580.
61. Miyaki, M.; Kuroki, T. Role of Smad4 (DPC4) inactivation in human cancer. Biochem. Biophys. Res. Commun. 2003, 306, 799–804.
62. Chen, H.-S.; Bai, M.-H.; Zhang, T.; Li, G.-D.; Liu, M. Ellagic acid induces cell cycle arrest and apoptosis through TGF- β /Smad3 signaling pathway in human breast cancer MCF-7 cells. Int. J. Oncol. 2015, 46, 1730–1738.
63. Cheng, J.-C.; Auersperg, N.; Leung, P.C. TGF- β induces serous borderline ovarian tumor cell invasion by activating EMTEMT but triggers apoptosis in low-grade serous ovarian carcinoma cells. PLoS ONE 2012, 7, e42436.
64. Massagué, J. TGF β signalling in context. Nat. Rev. Mol. Cell Biol. 2012, 13, 616–630.
65. Ho, J.; de Guise, C.; Kim, C.; Lemay, S.; Wang, X.-F.; Lebrun, J.-J. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase Inhibitor p15 INK4b and Sp1. Cell. Signal. 2004, 16, 693–701.
66. Kim, Y.K.; Bae, G.-U.; Kang, J.K.; Park, J.W.; Lee, E.K.; Lee, H.Y.; Choi, W.S.; Lee, H.W.; Han, J.-W. Cooperation of H2O2-mediated ERK activation with Smad pathway in TGF- β 1 induction of p21 WAF1/Cip1. Cell. Signal. 2006, 18, 236–243.
67. Shi, Y.; Massagué, J. Mechanisms of TGF- β signaling from cell membrane to the nucleus. Cell 2003, 113, 685–700.
68. Fuxe, J.; Vincent, T.; Garcia de Herreros, A. Transcriptional crosstalk between TGF β and stem cell pathways in tumor cell invasion: Role of EMT promoting SMAD complexes. Cell Cycle 2010, 9, 2363–2374.
69. Chen, X.-F.; Zhang, H.-J.; Wang, H.-B.; Zhu, J.; Zhou, W.-Y.; Zhang, H.; Zhao, M.-C.; Su, J.-M.; Gao, W.; Zhang, L. Transforming growth factor- β 1 induces epithelial-to-mesenchymal transition in human lung cancer cells via PI3K/Akt and MEK/Erk1/2 signaling pathways. Mol. Biol. Rep. 2012, 39, 3549–3556.
70. Zhang, Y.E. Non-SMAD pathways in TGF- β signaling. Cell Res. 2009, 19, 128–139.
71. Bakin, A.V.; Tomlinson, A.K.; Bhowmick, N.A.; Moses, H.L.; Arteaga, C.L. Phosphatidylinositol 3-kinase function is required for transforming growth factor β -mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 2000, 275, 36803–36810.
72. Lamouille, S.; Derynck, R. Cell size and invasion in TGF- β -induced epithelial to mesenchymal transition is regulated by activation of the mtor pathway. J. Cell Biol. 2007, 178, 437–451.
73. Shin, I.; Bakin, A.V.; Rodeck, U.; Brunet, A.; Arteaga, C.L. Transforming growth factor β enhances epithelial cell survival via Akt-dependent regulation of fkhrl1. Mol. Biol. Cell 2001, 12, 3328–3339.
74. Song, K.; Wang, H.; Krebs, T.L.; Danielpour, D. Novel roles of Akt and mTOR in suppressing TGF- β /Alk5-mediated Smad3 activation. EMBO J. 2006, 25, 58–69.
75. Masszi, A.; Di Ciano, C.; Sirokmany, G.; Arthur, W.T.; Rotstein, O.D.; Wang, J.; McCulloch, C.A.; Rosivall, L.; Mucsi, I.; Kapus, A. Central role for rho in TGF- β 1-induced β -smooth muscle actin expression during epithelial-mesenchymal transition. Am. J. Physiol.-Ren. Physiol. 2003, 284, F911–F924.
76. Mu, Y.; Gudey, S.K.; Landström, M. Non-Smad signaling pathways. Cell Tissue Res. 2012, 347, 11–20.
77. Yamamura, Y.; Hua, X.; Bergelson, S.; Lodish, H.F. Critical role of SMADs and AP-1 complex in transforming growth factor- β -dependent apoptosis. J. Biol. Chem. 2000, 275, 36295–36302.
78. Datto, M.B.; Li, Y.; Panus, J.F.; Howe, D.J.; Xiong, Y.; Wang, X.-F. Transforming growth factor β induces the cyclin-dependent kinase Inhibitor p21 through a p53-independent mechanism. Proc. Natl. Acad. Sci. USA 1995, 92, 5545–5549.
79. Barcellos-Hoff, M.H.; Akhurst, R.J. Transforming growth factor- β in breast cancer: Too much, too late. Breast Cancer Res. 2009, 11, 202.
80. Arteaga, C.L. Inhibition of TGF β signaling in cancer therapy. Curr. Opin. Genet. Dev. 2006, 16, 30–37.
81. Terabe, M.; Ambrosino, E.; Takaku, S.; O’Konek, J.J.; Venzon, D.; Lonning, S.; McPherson, J.M.; Berzofsky, J.A. Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti–transforming growth factor- β monoclonal antibody. Clin. Cancer Res. 2009, 15, 6560–6569.
82. Morris, J.; Shapiro, G.; Tan, A.; Lawrence, D.; Olencki, T.; Dezube, B.; Hsu, F.; Reiss, M.; Berzofsky, J. Phase I/II study of GC1008: A human anti-transforming growth factor- β (TGF β) monoclonal antibody (MAb) in patients with advanced malignant melanoma (MM) or renal cell carcinoma (RCC). J. Clin. Oncol. 2008, 26, 9028.
83. Morris, J.C.; Tan, A.R.; Olencki, T.E.; Shapiro, G.I.; Dezube, B.J.; Reiss, M.; Hsu, F.J.; Berzofsky, J.A.; Lawrence, D.P. Phase I study of GC1008 (fresolimumab): A human anti-transforming growth factor- β (TGF- β) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS ONE 2014, 9, e90353.
84. Han, J.; Alvarez-Breckenridge, C.A.; Wang, Q.-E.; Yu, J. TGF- β signaling and its targeting for glioma treatment. Am. J. Cancer Res. 2015, 5, 945–955.
85. Schlingensiepen, K.H.; Jaschinski, F.; Lang, S.A.; Moser, C.; Geissler, E.K.; Schlitt, H.J.; Kielmanowicz, M.; Schneider, A. Transforming growth factor- β 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci. 2011, 102, 1193–1200.
86. Tanaka, H.; Shinto, O.; Yashiro, M.; Yamazoe, S.; Iwauchi, T.; Muguruma, K.; Kubo, N.; Ohira, M.; Hirakawa, K. Transforming growth factor β signaling inhibitor, SB-431542, induces maturation of dendritic cells and enhances anti-tumor activity. Oncol. Rep. 2010, 24, 1637–1643.
87. Wendt, M.K.; Smith, J.A.; Schiemann, W.P. Transforming growth factor- β -induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 2010, 29, 6485–6498.
88. Melisi, D.; Ishiyama, S.; Sclabas, G.M.; Fleming, J.B.; Xia, Q.; Tortora, G.; Abbruzzese, J.L.; Chiao, P.J. LY2109761, a novel transforming growth factor β receptor type i and type ii dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 2008, 7, 829–840.
89. Zhong, Z.; Carroll, K.D.; Policarpio, D.; Osborn, C.; Gregory, M.; Bassi, R.; Jimenez, X.; Prewett, M.; Liebisch, G.; Persaud, K. Anti-transforming growth factor β receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells. Clin. Cancer Res. 2010, 16, 1191–1205.
90. Zhao, B.M.; Hoffmann, F.M. Inhibition of transforming growth factor- β 1-induced signaling and epithelial-to-mesenchymal transition by the Smad-binding peptide aptamer Trx-SARA. Mol. Biol. Cell 2006, 17, 3819–3831.
91. Yoo, Y.A.; Kang, M.H.; Lee, H.J.; Kim, B.-H.; Park, J.K.; Kim, H.K.; Kim, J.S.; Oh, S.C. Sonic hedgehog pathway promotes metastasis and lymphangiogenesis via activation of Akt, EMT, and MMP-9 pathway in gastric cancer. Cancer Res. 2011, 71, 7061–7070.
92. Xu, X.; Zhou, Y.; Xie, C.; Wei, S.; Gan, H.; He, S.; Wang, F.; Xu, L.; Lu, J.; Dai, W. Genome-wide screening reveals an EMT molecular network mediated by Sonic hedgehog-Gli1 signaling in pancreatic cancer cells. PLoS ONE 2012, 7, e43119.
93. Islam, S.; Mokhtari, R.; Noman, A.; Uddin, M.; Rahman, M.; Azadi, M.; Zlotta, A.; van der Kwast, T.; Yeger, H.; Farhat, W. Sonic hedgehog (SHH) signaling promotes tumorigenicity and stemness via activation of epithelial-to-mesenchymal transition (EMT) in bladder cancer. Mol. Carcinog. 2015.
94. Chen, M.-H.; Li, Y.-J.; Kawakami, T.; Xu, S.-M.; Chuang, P.-T. Palmitoylation is required for the production of a soluble multimeric hedgehog protein complex and long-range signaling in vertebrates. Genes Dev. 2004, 18, 641–659.
95. Jiang, J.; Hui, C.-C. Hedgehog signaling in development and cancer. Dev. Cell 2008, 15, 801–812.
96. Takebe, N.; Harris, P.J.; Warren, R.Q.; Ivy, S.P. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat.Rev. Clin. Oncol. 2011, 8, 97–106.
97. Stone, D.M.; Hynes, M.; Armanini, M.; Swanson, T.A.; Gu, Q.; Johnson, R.L.; Scott, M.P.; Pennica, D.; Goddard, A.; Phillips, H. The tumour-suppressor gene patched encodes a candidate receptor for Sonic hedgehog. Nature 1996, 384, 129–134.
98. Huangfu, D.; Anderson, K.V. Signaling from Smo to Ci/Gli: Conservation and divergence of hedgehog pathways from Drosophila to vertebrates. Development 2006, 133, 3–14.
99. Murone, M.; Rosenthal, A.; de Sauvage, F.J. Sonic hedgehog signaling by the patched-smoothened receptor complex. Curr. Biol. 1999, 9, 76–84.
100. Roessler, E.; Ermilov, A.N.; Grange, D.K.; Wang, A.; Grachtchouk, M.; Dlugosz, A.A.; Muenke, M. A previously unidentified amino-terminal domain regulates transcriptional activity of wild-type and disease-associated human GLI2. Hum. Mol. Genet. 2005, 14, 2181–2188.
101. Sasaki, H.; Nishizaki, Y.; Hui, C.-C.; Nakafuku, M.; Kondoh, H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: Implication of Gli2 and Gli3 as primary mediators of Shh signaling. Development 1999, 126, 3915–3924.
102. Varjosalo, M.; Taipale, J. Hedgehog: Functions and mechanisms. Genes Dev. 2008, 22, 2454–2472.
103. Regl, G.; Neill, G.W.; Eichberger, T.; Kasper, M.; Ikram, M.S.; Koller, J.; Hintner, H.; Quinn, A.G.; Frischauf, A.-M.; Aberger, F. Human Gli2 and Gli1 are part of a positive feedback mechanism in basal cell carcinoma. Oncogene 2002, 21, 5529–5539.
104. Amakye, D.; Jagani, Z.; Dorsch, M. Unraveling the therapeutic potential of the hedgehog pathway in cancer. Nat. Med. 2013, 19, 1410–1422.
105. Katoh, Y.; Katoh, M. Hedgehog target genes: Mechanisms of carcinogenesis induced by aberrant hedgehog signaling activation. Curr. Mol. Med. 2009, 9, 873–886.
106. Wang, X.; Venugopal, C.; Manoranjan, B.; McFarlane, N.; O’Farrell, E.; Nolte, S.; Gunnarsson, T.; Hollenberg, R.; Kwiecien, J.; Northcott, P. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012, 31, 187–199.
107. Zbinden, M.; Duquet, A.; Lorente-Trigos, A.; Ngwabyt, S.N.; Borges, I.; i Altaba, A.R. NANOG regulates glioma stem cells and is essential in vivo acting in a cross-functional network with Gli1 and p53. EMBO J. 2010, 29, 2659–2674.
108. Li, X.; Deng, W.; Nail, C.D.; Bailey, S.K.; Kraus, M.H.; Ruppert, J.M.; Lobo-Ruppert, S.M. Snail induction is an early response to Gli1 that determines the efficiency of epithelial transformation. Oncogene 2006, 25, 609–621.
109. Li, X.; Deng, W.; Lobo-Ruppert, S.M.; Ruppert, J.M. Gli1 acts through Snail and E-cadherin to promote nuclear signaling by β -catenin. Oncogene 2007, 26, 4489–4498.
110. Villavicencio, E.H.; Yoon, J.W.; Frank, D.J.; Füchtbauer, E.M.; Walterhouse, D.O.; Iannaccone, P.M. Cooperative E-box regulation of human GLI1 by TWIST and USF. Genesis 2002, 32, 247–258.
111. Dennler, S.; André, J.; Alexaki, I.; Li, A.; Magnaldo, T.; Ten Dijke, P.; Wang, X.-J.; Verrecchia, F.; Mauviel, A. Induction of sonic hedgehog mediators by transforming growth factor- β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 2007, 67, 6981–6986.
112. Dennler, S.; André, J.; Verrecchia, F.; Mauviel, A. Cloning of the human GLI2 promoter transcriptional activation by transforming growth factor- β via Smad3/ β -catenin cooperation. J. Biol. Chem. 2009, 284, 31523–31531.
113. Javelaud, D.; Alexaki, V.I.; Dennler, S.; Mohammad, K.S.; Guise, T.A.; Mauviel, A. TGF- β /SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res. 2011, 71, 5606–5610.
114. Yang, L.; Xie, G.; Fan, Q.; Xie, J. Activation of the hedgehog-signaling pathway in human cancer and the clinical implications. Oncogene 2010, 29, 469–481.
115. Bian, X.-H.; Sun, H.; Xue, H.; Zhang, G.; Zhang, C.-H.; Liu, X.-L.; Su, J.; Li, S.-J. Expression and clinical significance of Shh/Gli-1 in papillary thyroid carcinoma. Tumor Biol. 2014, 35, 10523–10528.
116. Yue, D.; Li, H.; Che, J.; Zhang, Y.; Tseng, H.-H.K.; Jin, J.Q.; Luh, T.M.; Giroux-Leprieur, E.; Mo, M.; Zheng, Q. Hedgehog/Gli promotes epithelial-mesenchymal transition in lung squamous cell carcinomas. J. Exp. Clin. Cancer Res. 2014, 33, 34.
117. Behnsawy, H.M.; Shigemura, K.; Meligy, F.Y.; Yamamichi, F.; Yamashita, M.; Haung, W.-C.; Li, X.; Miyake, H.; Tanaka, K.; Kawabata, M. Possible role of sonic hedgehog and epithelial-mesenchymal transition in renal cell cancer progression. Korean J. Urol. 2013, 54, 547–554.
118. Bermudez, O.; Hennen, E.; Koch, I.; Lindner, M.; Eickelberg, O. Gli1 mediates lung cancer cell proliferation and sonic hedgehog-dependent mesenchymal cell activation. PLoS ONE 2013, 8, e63226.
119. Ruiz i Altaba, A.; Sánchez, P.; Dahmane, N. Gli and hedgehog in cancer: Tumours, embryos and stem cells. Nat. Rev. Cancer 2002, 2, 361–372.
120. Feldmann, G.; Dhara, S.; Fendrich, V.; Bedja, D.; Beaty, R.; Mullendore, M.; Karikari, C.; Alvarez, H.; Iacobuzio-Donahue, C.; Jimeno, A. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 2007, 67, 2187–2196.
121. LoRusso, P.M.; Rudin, C.M.; Reddy, J.C.; Tibes, R.; Weiss, G.J.; Borad, M.J.; Hann, C.L.; Brahmer, J.R.; Chang, I.; Darbonne, W.C. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin. Cancer Res. 2011, 17, 2502–2511.
122. Kaye, S.B.; Fehrenbacher, L.; Holloway, R.; Amit, A.; Karlan, B.; Slomovitz, B.; Sabbatini, P.; Fu, L.; Yauch, R.L.; Chang, I. A phase II, randomized, placebo-controlled study of vismodegib as maintenance therapy in patients with ovarian cancer in second or third complete remission. Clin. Cancer Res. 2012, 18, 6509–6518.
123. Singh, B.N.; Fu, J.; Srivastava, R.K.; Shankar, S. Hedgehog signaling antagonist GDC-0449 (vismodegib) inhibits pancreatic cancer stem cell characteristics: Molecular mechanisms. PLoS ONE 2011, 6, e27306.
124. Lauth, M.; Bergström, Å.; Shimokawa, T.; Toftgård, R. Inhibition of GLI-mediated transcription and tumor cell growth by small-molecule antagonists. Proc. Natl. Acad. Sci. USA 2007, 104, 8455–8460.
125. Peifer, M.; Polakis, P. Wnt signaling in oncogenesis and embryogenesis—A look outside the nucleus. Science 2000, 287, 1606–1609.
126. Zhou, B.P.; Hung, M.-C. Wnt, hedgehog, and SNAIL: Sister pathways that control by GSK-3 β and β -Trcp in the regulation of metastasis. Cell Cycle 2005, 4, 772–776.
127. Fodde, R.; Brabletz, T. Wnt/ β -catenin signaling in cancer stemness and malignant behavior. Curr. Opin. Cell Biol. 2007, 19, 150–158.
128. Easwaran, V.; Pishvaian, M.; Byers, S. Cross-regulation of β -catenin-LEF/TCF and retinoid signaling pathways. Curr. Biol. 1999, 9, 1415–1419.
129. Stemmer, V.; De Craene, B.; Berx, G.; Behrens, J. Snail promotes Wnt target gene expression and interacts with β -catenin. Oncogene 2008, 27, 5075–5080.
130. Orsulic, S.; Huber, O.; Aberle, H.; Arnold, S.; Kemler, R. E-cadherin binding prevents β -catenin nuclear localization and β -catenin/LEF-1-mediated transactivation. J. Cell Sci. 1999, 112, 1237–1245.
131. Yook, J.I.; Li, X.-Y.; Ota, I.; Hu, C.; Kim, H.S.; Kim, N.H.; Cha, S.Y.; Ryu, J.K.; Choi, Y.J.; Kim, J. A Wnt-Axin2-GSK3 β cascade regulates Snail1 activity in breast cancer cells. Nat. Cell Biol. 2006, 8, 1398–1406.
132. Mizuarai, S.; Kawagishi, A.; Kotani, H. Inhibition of p70S6K2 down-regulates Hedgehog/GLI pathway in non-small cell lung cancer cell lines. Mol. Cancer 2009, 8, 44.
133. Takenaka, K.; Kise, Y.; Miki, H. GSK3 β positively regulates Hedgehog signaling through Sufu in mammalian cells. Biochem. Biophys. Res. Commun. 2007, 353, 501–508.
134. Noubissi, F.K.; Goswami, S.; Sanek, N.A.; Kawakami, K.; Minamoto, T.; Moser, A.; Grinblat, Y.; Spiegelman, V.S. Wnt signaling stimulates transcriptional outcome of the Hedgehog pathway by stabilizing GLI1 mRNA. Cancer Res. 2009, 69, 8572–8578.
135. Caraci, F.; Gili, E.; Calafiore, M.; Failla, M.; La Rosa, C.; Crimi, N.; Sortino, M.A.; Nicoletti, F.; Copani, A.; Vancheri, C. TGF- β 1 targets the GSK-3 β/β -catenin pathway via ERK activation in the transition of human lung fibroblasts into myofibroblasts. Pharmacol. Res. 2008, 57, 274–282.
136. Guo, X.; Ramirez, A.; Waddell, D.S.; Li, Z.; Liu, X.; Wang, X.-F. Axin and GSK3- β control Smad3 protein stability and modulate TGF- β signaling. Genes Dev. 2008, 22, 106–120.
137. Takahashi-Yanaga, F.; Kahn, M. Targeting wnt signaling: Can we safely eradicate cancer stem cells? Clin. Cancer Res. 2010, 16, 3153–3162.
138. Kahn, M. Can we safely target the Wnt pathway? Nat. Rev. Drug Discov. 2014, 13, 513–532.
139. Gala, M.K.; Chan, A.T. Molecular pathways: Aspirin and Wnt signaling—A molecularly targeted approach to cancer prevention and treatment. Clin. Cancer Res. 2015, 21, 1543–1548.
140. Revenu, C.; Gilmour, D. EMT 2.0: Shaping epithelia through collective migration. Curr. Opin. Genet. Dev. 2009, 19, 338–342.
141. Tam, W.L.; Weinberg, R.A. The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat. Med. 2013, 19, 1438–1449.
142. Tian, X.-J.; Zhang, H.; Xing, J. Coupled reversible and irreversible bistable switches underlying TGF β -induced epithelial to mesenchymal transition. Biophys. J. 2013, 105, 1079–1089.
143. Siemens, H.; Jackstadt, R.; Hünten, S.; Kaller, M.; Menssen, A.; Götz, U.; Hermeking, H. miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions. Cell Cycle 2011, 10, 4256–4271.
144. Zhang, J.; Tian, X.-J.; Zhang, H.; Teng, Y.; Li, R.; Bai, F.; Elankumaran, S.; Xing, J. TGF- β -induced epithelial-to-mesenchymal transition proceeds through stepwise activation of multiple feedback loops. Sci. Signal. 2014, 7, ra91.
145. Hong, T.; Watanabe, K.; Ta, C.H.; Villarreal-Ponce, A.; Nie, Q.; Dai, X. An Ovol2-Zeb1 mutual inhibitory circuit governs bidirectional and multi-step transition between epithelial and mesenchymal states. PLoS Comput. Biol. 2015, 11, e1004569.
146. Huang, R.Y.; Wong, M.; Tan, T.; Kuay, K.; Ng, A.; Chung, V.; Chu, Y.; Matsumura, N.; Lai, H.; Lee, Y. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to E-cadherin restoration by a src-kinase Inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013, 4, e915.
147. Steinway, S.N.; Zañudo, J.G.; Ding, W.; Rountree, C.B.; Feith, D.J.; Loughran, T.P.; Albert, R. Network modeling of TGF- β signaling in hepatocellular carcinoma epithelial-to-mesenchymal transition reveals joint sonic hedgehog and wnt pathway activation. Cancer Res. 2014, 74, 5963–5977.
148. Steinway, S.N.; Zañudo, J.G.T.; Michel, P.J.; Feith, D.J.; Loughran, T.P.; Albert, R. Combinatorial interventions inhibit TGF- β -driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes. NPJ Syst. Biol. Appl. 2015, 1, 15014.
149. Nam, S.; Chang, H.; Kim, K.; Kook, M.; Hong, D.; Kwon, C.; Jung, H.; Park, H.; Powis, G.; Liang, H. Pathome: An algorithm for accurately detecting differentially expressed subpathways. Oncogene 2014, 33, 4941–4951.
150. Behar, M.; Barken, D.; Werner, S.L.; Hoffmann, A. The dynamics of signaling as a pharmacological target. Cell 2013, 155, 448–461.
151. Lee, M.J.; Albert, S.Y.; Gardino, A.K.; Heijink, A.M.; Sorger, P.K.; MacBeath, G.; Yaffe, M.B. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012, 149, 780–794.
152. Kreeger, P.K.; Lauffenburger, D.A. Cancer systems biology: A network modeling perspective. Carcinogenesis 2010, 31, 2–8.
153. Bakan, A.; Kapralov, A.A.; Bayir, H.; Hu, F.; Kagan, V.E.; Bahar, I. Inhibition of peroxidase activity of cytochrome c: De novo compound discovery and validation. Mol. Pharmacol. 2015, 88, 421–427.